MARKET

VINC

VINC

Vincerx Pharma Inc
NASDAQ
0.5800
+0.0196
+3.50%
After Hours: 0.6000 +0.02 +3.45% 19:56 03/25 EDT
OPEN
0.5985
PREV CLOSE
0.5604
HIGH
0.5994
LOW
0.5331
VOLUME
315.79K
TURNOVER
0
52 WEEK HIGH
136.80
52 WEEK LOW
0.4860
MARKET CAP
1.30M
P/E (TTM)
-0.0281
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VINC last week (0317-0321)?
Weekly Report · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign
Reuters · 03/18 17:47
BUZZ-Vincerx Pharma soars on QumulusAI merger deal
Reuters · 03/18 14:14
Vincerx Pharma Shares Soar on Proposed Merger with Global Digital Holdings
Dow Jones · 03/18 13:34
VINCERX PHARMA : AS OF FEB 28, 2025, HAD ABOUT$3.9 MLN IN CASH AND ANTICIPATES ITS CASH RUNWAY WILL EXTEND INTO LATE Q2 2025
Reuters · 03/18 13:13
Vincerx Pharma Enters Non-Binding LOI With QumulusAI For Reverse Merger; QumulusAI To Own 95% Of Combined Entity Valued At $285M, Vincerx At $15M; QumulusAI Or Its Designees Will Invest Up To $1.5M In The Equity Of Vincerx Prior To Closing
Benzinga · 03/18 12:55
VINCERX PHARMA INC - QUMULUSAI TO INVEST UP TO $1.5 MILLION IN VINCERX EQUITY
Reuters · 03/18 12:52
Press Release: Vincerx Pharma Announces -2-
Dow Jones · 03/18 12:52
More
About VINC
More
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Recently
Symbol
Price
%Change

Webull offers Vincerx Pharma Inc stock information, including NASDAQ: VINC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VINC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VINC stock methods without spending real money on the virtual paper trading platform.